![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0015.png)
Page 53
allied
academies
Journal of Biotechnology and Phytochemistry| Volume: 2
October 25-26, 2018 | Frankfurt, Germany
Joint Event
Biotechnology & Medical Microbiology
World Congress on
3
rd
International Conference on
Food Science & Technology
APC-100, a novel pharmaceutical neuroregeneration therapy for the Alzheimer’s disease
Kiminobu Sugaya
University of Central Florida, USA
O
ne of the primary hurdles of Alzheimer’s disease (AD)
therapy is that it requires more then one solution to
successfully stop or reverse it since the disease degenerate
many different types of cells as compare to the other
neurodegenerative diseases. That is why the stem cells could
be useful to treat AD since they could produce those different
types of cells according to the environments. However, to use
stem cells, influences from the pathological environment of
AD must be addressed. The AD brain over produces amyloid
precursor protein (APP), which then results in amyloid plaques,
one of the hallmarks of AD. We found that the pathological
level of APP prevents neural stem cells (NSCs) to differentiate
into neurons. Our approach is to combine small molecule
therapeutics for both modifying the pathological condition
AD and increasing endogenous NSCs. With phenserine, a drug
reduces APP production, we were able to control the APP to a
normal level, which allows NSCs to differentiate into neurons.
Then we combined KS-217, a pyro pyrimidine derivative, which
pass through the blood brain barrier to increase endogenous
NSCs at the significant level, eliminating the need of NSCs
transplantation. This combination therapeutic approach
(APC-100) has proven effective in improving cognition and
increasing neuroregeneration in AD mice model. APC-100
will introduce totally new concept to AD stem cell therapy,
which does not require any transplantable cell materials.
e:
Kiminobu.Sugaya@ucf.edu